Group |
Type |
Cat. No. |
Product |
Activity |
β-catenin Peptides |
|
6531 |
NLS-StAx-h |
Wnt
signaling inhibitor; inhibits β-catenin-transcription factor interactions |
7298 |
xStAx-VHLL |
Selective
peptide-based β-catenin Degrader |
δ Opioid Receptor Peptides |
Agonists |
3790 |
DADLE |
Prototypical
δ agonist |
1180 |
[D-Ala2]-Deltorphin
II |
Selective
δ agonist peptide |
1431 |
DPDPE |
Selective
δ agonist |
Antagonists |
0820 |
ICI
174,864 |
δ
selective peptide antagonist |
κ Opioid Receptor Peptides |
Agonists |
3195 |
Dynorphin
A |
Endogenous
κ agonist |
7541 |
Helianorphin-19 |
Potent
and selective G protein-biased κ opioid receptor (KOR) agonist |
μ Opioid Receptor Peptides |
Agonists |
1171 |
DAMGO |
Selective
μ agonist |
1055 |
Endomorphin-1 |
Potent
and selective μ agonist |
Antagonists |
1560 |
CTAP |
Potent
and selective μ antagonist |
1578 |
CTOP |
Potent
and selective μ antagonist |
14.3.3 Protein Peptides |
Inhibitors |
2144 |
R18 |
Inhibitor
of 14.3.3 proteins |
A-Kinase-Anchoring Proteins Peptides |
Inhibitors |
6286 |
st-Ht31 |
Inhibits
PKA/AKAP interactions; cell permeable |
ACE2 Peptides |
Inhibitors |
5213 |
LL
37 |
Inhibitor
of SARS-CoV-2 S1 spike protein and ACE2 interaction |
Substrates |
1563 |
Angiotensin
I (human, mouse, rat) |
Potent
endogenous vasoconstrictor peptide; substrate for ACE and ACE2 |
1158 |
Angiotensin
II |
Potent
endogenous vasoconstrictor peptide; substrate for ACE2 |
Other |
7233 |
SBP1 |
ACE2
derived peptide; binds SARS-CoV-2 spike protein receptor binding domain |
7322 |
SP
10 |
Highly
potent inhibitor of SARS-CoV Spike (S) protein and ACE2 interaction |
Acid-Sensing Ion Channel Peptides |
Blockers |
4804 |
APETx2 |
ASIC3
channel blocker |
5042 |
Psalmotoxin
1 |
Potent
and selective ASIC1a channel blocker |
Actin Peptides |
|
4535 |
Phalloidin |
Promotes
actin polymerization |
Active Degrader Peptides |
Degraders |
7388 |
ND1-YL2 |
SRC-1
peptide-based PROTAC®; active in vivo |
7298 |
xStAx-VHLL |
Selective
peptide-based β-catenin Degrader (PROTAC®) |
ADAM Peptides |
Inhibitors |
5523 |
TAPI
0 |
ADAM-17
(TACE) and MMP inhibitor |
6162 |
TAPI
1 |
ADAM-17
(TACE) and MMP inhibitor |
6013 |
TAPI
2 |
ADAM-17
(TACE) and MMP inhibitor |
Adenylyl Cyclase Peptides |
Activators |
1183 |
PACAP
1-27 |
Potently
stimulates adenylyl cyclase |
1186 |
PACAP
1-38 |
Potently
stimulates adenylyl cyclase |
Amyloid β Peptide Peptides |
Inhibitors |
6779 |
Davunetide |
Highly
potent active component of ADNP; prevents amyloid β aggregation;
active in vivo |
Other |
1191 |
Amyloid
β-Peptide (1-40) (human) |
Amyloid
β-protein fragment |
1428 |
Amyloid
β-Peptide (1-42) (human) |
Predominant
amyloid β-protein fragment |
2425 |
Amyloid
β-peptide (1-42) (rat) |
Predominant
amyloid β-protein fragment |
1429 |
Amyloid
β-peptide (25-35) (human) |
Human
amyloid β-protein fragment functionally required for neurotoxicity |
3945 |
Colivelin |
Neuroprotective
peptide; protects against β-amyloid neurotoxicity |
6517 |
Liraglutide |
Reduces
Aβ and soluble amyloid levels in vivo; also highly potent GLP-1 receptor
agonist |
7712 |
Semax |
Reduces
Aβ aggregation and fibrillogenesis; neuroprotective and neurotrophic peptide |
Angiotensin AT2 Receptor Peptides |
Ligands |
2569 |
CGP
42112 |
Selective,
high affinity AT2 ligand |
Angiotensin- Converting Enzyme Peptides |
Substrates |
1563 |
Angiotensin
I (human, mouse, rat) |
Endogenous
peptide substrate of ACE and ACE2 |
3791 |
Hemopressin
(human, mouse) |
Bioactive
substrate for endopeptidase 24.15, neurolysin and ACE |
Antiangiogenic Peptides |
Inhibitors |
4664 |
Obtustatin |
Potent
and selective α1β1 inhibitor; antiangiogenic |
AP-1 Peptides |
Inhibitors |
1989 |
c-JUN
peptide |
JNK/c-Jun
interaction inhibitor |
Apelin Receptor Peptides |
Agonists |
2420 |
[Pyr1]-Apelin-13 |
Potent
peptide apelin agonist |
3007 |
Apelin-17
(human, bovine) |
Endogenous
apelin agonist |
2426 |
Apelin-36
(human) |
Endogenous
apelin agonist |
Antagonists |
5992 |
MM
54 |
Potent
apelin antagonist |
Autophagy Peptides |
Inhibitors |
1190 |
Pepstatin
A |
Protease
inhibitor; interferes with autolysosomal digestion |
Biochemicals and Molecular Biology Peptides |
|
7723 |
RGD
peptide |
Directs
association of cells with diverse biomaterials and surfaces |
Blocking Buffer and Reagent Peptides |
|
5217 |
Bovine
Serum Albumin |
Blocking
reagent used in blocking buffer for use in ICC and IHC |
Bombesin Receptor Peptides |
Agonists |
1789 |
GRP
(human) |
Endogenous
GRP receptor agonist |
Other |
1908 |
Neuromedin
B (porcine) |
Mammalian
bombesin-like peptide |
Bradykinin Receptor Peptides |
Agonists |
3004 |
Bradykinin |
Endogenous
agonist at bradykinin receptors (B2 > B1) |
3229 |
[Phe8Ψ(CH-NH)-Arg9]-Bradykinin |
Selective
B2 agonist |
3225 |
Lys-[Des-Arg9]Bradykinin |
Selective
B1 agonist |
Antagonists |
3014 |
HOE
140 |
Potent
and selective B2 antagonist |
3407 |
R
715 |
Potent
and selective B1 antagonist |
Buffers, Solvents and Solution Peptides |
|
5217 |
Bovine
Serum Albumin |
BSA
(bovine serum albumin) is a blocking buffer for IHC, ICC, ELISA and Western
blotting; used to block non-specific antibody binding. Commonly used in cell
culture |
CaV2.x Channel Peptides |
Blockers |
2799 |
ω-Agatoxin
IVA |
CaV2.1
blocker |
2802 |
ω-Agatoxin
TK |
CaV2.1
blocker |
1085 |
ω-Conotoxin
GVIA |
CaV2.2
blocker |
2945 |
SNX
482 |
Potent
and selective CaV2.3 blocker |
Calcitonin and Related Receptor Peptides |
Agonists |
3418 |
Amylin |
Endogenous
peptide agonist for amylin, calcitonin, CGRP and adrenomedullin receptors |
6031 |
Calcitonin
(human) |
Endogenous
calcitonin agonist; inhibits bone resorption |
1159 |
Calcitonin
(salmon) |
Affects
bone formation and resorption |
3012 |
α-CGRP
(human) |
CGRP
agonist |
1161 |
CGRP
(rat) |
Potent
vasodilator |
5031 |
Pramlintide |
Synthetic
version of amylin (Cat. No. 3418) |
Antagonists |
3419 |
AC
187 |
Potent
and selective amylin antagonist |
1181 |
CGRP
8-37 (human) |
CGRP
antagonist |
1169 |
CGRP
8-37 (rat) |
CGRP
antagonist |
Calcium Binding Protein Peptides |
Agonists |
2090 |
CALP1 |
Cell-permeable
calmodulin agonist |
Inhibitors |
1688 |
Autocamtide-2-related
inhibitory peptide |
Selective
CaM kinase II inhibitor |
5959 |
Autocamtide-2-related
inhibitory peptide, myristoylated |
CaM
kinase II inhibitor; enhanced cell permeable derivative
of Autocamtide-2-related inhibitory peptide |
1885 |
MLCK
inhibitor peptide 18 |
Selective
inhibitor of myosin light chain kinase |
Calcium-Activated Potassium (KCa) Channel Peptides |
Blockers |
1652 |
Apamin |
KCa2
(SK) channel blocker |
1086 |
Iberiotoxin |
KCa (BK)
channel blocker |
Calcium-Sensitive Protease Peptides |
Inhibitors |
2950 |
Acetyl-Calpastatin
(184-210) (human) |
Selective
calpain inhibitor |
Calmodulin- Dependent Kinase Peptides |
Inhibitors |
1688 |
Autocamtide-2-related
inhibitory peptide |
Selective
CaM kinase II inhibitor |
5959 |
Autocamtide-2-related
inhibitory peptide, myristoylated |
CaM
kinase II inhibitor; enhanced cell permeable derivative
of Autocamtide-2-related inhibitory peptide |
Calpain Peptides |
Inhibitors |
2950 |
Acetyl-Calpastatin
(184-210) (human) |
Selective
calpain inhibito |
Caspase Peptides |
Inhibitors |
7242 |
Ac-FLTD-CMK |
Potent
and selective inhibitor of caspases 1, 5 and 4 |
2166 |
Z-DEVD-FMK |
Cell-permeable,
irreversible caspase-3 inhibitor |
8009 |
Z-DEVD-FMK
Caspase-3 Inhibitor New |
Caspase-3
Inhibitor |
2163 |
Z-VAD-FMK |
Cell-permeable,
irreversible caspase inhibitor |
Cathepsin Peptides |
Inhibitors |
1190 |
Pepstatin
A |
Selective
and high affinity cathepsin D inhibitor |
CB1 Receptor Peptides |
Inverse
Agonists |
3791 |
Hemopressin
(human, mouse) |
Selective
CB1 inverse agonist |
CCK1 Receptor Peptides |
Agonists |
2411 |
A-71623 |
Potent
and selective CCK1 agonist; suppresses feeding |
CCK2 Receptor Peptides |
Agonists |
3006 |
Gastrin
I (human) |
Selective
CCK2 agonist |
Cell Adhesion Molecule Peptides |
Inhibitors |
7723 |
RGD
peptide |
Minimal
recognition sequence for integrin binding; potent integrin inhibitor |
Other |
1845 |
Ac2-26 |
Annexin/lipocortin
1-mimetic; inhibits leukocyte extravasation |
3910 |
BIO
1211 |
Selective
α4β1 (VLA-4) inhibitor |
5870 |
Cilengitide |
Potent
and selective inhibitor of integrins αvβ3 and αvβ5 |
3202 |
Echistatin,
α1 isoform |
Integrin
αVβ3 and glycoprotein IIb/IIIa (integrin αIIbβ3) inhibitor |
4725 |
Eptifibatide |
Glycoprotein
IIb/IIIa inhibitor; inhibits platelet aggregation |
4577 |
LDV
FITC |
Fluorescent
ligand for α4β1 (VLA-4) |
4664 |
Obtustatin |
Potent
and selective α1β1 inhibitor |
3498 |
RGDS
peptide |
Integrin
binding sequence; inhibits integrin receptor function |
Chemokine CC Receptor Peptides |
Antagonists |
2423 |
DAPTA |
Chemokine
receptor 5 (CCR5) antagonist |
Chemokine CXC Receptor Peptides |
Agonists |
5795 |
ATI
2341 |
CXCR4
allosteric agonist |
Antagonists |
5130 |
CTCE
9908 |
CXCR4
antagonist; antitumor |
4300 |
TC
14012 |
CXCR4
antagonist; ACKR3 (CXCR7) agonist |
Complement Peptides |
Antagonists |
5196 |
PMX
205 |
Potent
C5a receptor peptide antagonist |
5473 |
PMX
53 |
Potent
C5a receptor antagonist |
Controls |
3796 |
Compstatin
control peptide |
Control
peptide for Compstatin (Cat. No. 2585) |
5697 |
PMX
53c |
Negative
control for PMX 53 (Cat. No. 5473) |
Other |
2585 |
Compstatin |
C3-binding
peptide; inhibits complement activation |
Coronavirus Antiviral Peptides |
|
5213 |
LL
37 |
Inhibits
interaction between SAR-CoV-2 S1 protein and ACE2; human cathelicidin peptide
derivative |
CRF1 Receptor Peptides |
Agonists |
1608 |
Stressin
I |
CRF1 agonist |
CRF2 Receptor Peptides |
Agonists |
2391 |
Astressin
2B |
Selective
CRF2 antagonist |
2070 |
K
41498 |
Highly
selective and potent CRF2 antagonist |
Cytokine Receptor Peptides |
Antagonists |
1793 |
AF
12198 |
Potent,
selective human type I IL-1 receptor antagonis |
Dynamin Peptides |
Inhibitors |
1774 |
Dynamin
inhibitory peptide |
Dynamin
inhibitor |
1775 |
Dynamin
inhibitory peptide, myristoylated |
Cell-permeable
dynamin inhibitor |
6897 |
P110 |
Dynamin-related
protein 1 (Drp1) inhibitor; cell-permeable |
Enzyme Probes and Enzyme Substrate Peptides |
|
7287 |
FAM-DEALA-Hyp-YIPD |
Fluorescent
HIF-1α peptide; can be used to evaluate the effect of VHL binding on
degradation activity |
7452 |
FAM-DEALAHypYIPMDDDFQLRSF |
Fluorescent
HIF-1α peptide |
7627 |
FITC-labelled
Keap1-Nrf2 probe |
Fluorescent
Keap1-Nrf2 peptide |
Enzyme Substrate / Activator Peptides |
Substrates |
3791 |
Hemopressin
(human, mouse) |
Bioactive
substrate for endopeptidase 24.15, neurolysin and ACE |
Activators |
1983 |
740
Y-P |
Cell-permeable
PI 3-kinase activator |
Eph Receptor Peptides |
Inhibitors |
5290 |
KYL |
EphA4
kinase inhibitor; neuroprotective |
ETA Receptor Peptides |
Antagonists |
1188 |
BQ-123 |
Selective
ETA antagonist |
ETB Receptor Peptides |
Agonists |
1189 |
BQ-3020 |
Selective
ETB agonist |
1196 |
IRL-1620 |
Highly
selective ETB agonist |
1175 |
Sarafotoxin
S6c |
Selective
ETB agonist |
Fluorescent Integrin Probe Peptides |
|
4577 |
LDV
FITC |
Fluorescent
ligand for α4β1 (VLA-4) |
Fluorescent Receptor Probe Peptides |
|
4577 |
LDV
FITC |
Fluorescent
ligand for α4β1 (VLA-4) |
Formyl Peptide Receptor Peptides |
Agonists |
1921 |
N-Formyl-Met-Leu-Phe |
Endogenous
FPR1 agonist |
3537 |
MMK
1 |
Potent
and selective FPR2 agonist |
1800 |
WKYMVm |
FPR1,
FPR2 and FPR3 receptor agonist |
Antagonists |
3730 |
Boc-MLF |
FPR1
antagonist |
4611 |
PBP
10 |
Selective
FPR2 antagonist; cell permeable |
2262 |
WRW4 |
Selective
FPR2 antagonist |
Furin Peptides |
Inhibitors |
3501 |
Decanoyl-RVKR-CMK |
Furin
inhibitor; blocks SARS-CoV-2 spike protein cleavage and blocks viral cell
entry |
4711 |
Hexa-D-arginine |
Furin
inhibitor |
Galanin Receptor Peptides |
Agonists |
2696 |
Galanin
(1-29) (rat, mouse) |
Non-selective
galanin receptor agonist |
1179 |
Galanin
(1-30) (human) |
Endogenous
galanin receptor agonist |
2697 |
M617 |
Selective
GAL1 agonist |
6090 |
Spexin |
Potent
GAL2/3 agonist; exhibits anxiolytic effects in vivo |
Antagonists |
3425 |
M40 |
Potent,
non-selective galanin receptor antagonist |
2698 |
M871 |
Selective
GAL2 antagonist |
Gap Channel Peptides |
Blockers |
3348 |
10Panx |
Panx-1
mimetic inhibitory peptide; blocks pannexin-1 gap junctions |
1950 |
Gap
26 |
Gap
junction blocker; inhibits smooth muscle contraction and IP3-mediated ATP
release |
1476 |
Gap
27 |
Selective
gap junction blocker |
5353 |
Gap19 |
Cx43
hemichannel blocker |
6227 |
TAT-Gap19 |
Cx43
hemichannel blocker |
Controls |
7402 |
TAT-Gap19(I130A) |
Control
peptide for TAT-Gap19 |
Ghrelin Receptor Peptides |
Agonists |
1463 |
Ghrelin
(human) |
Endogenous
ghrelin receptor agonist |
1465 |
Ghrelin
(rat) |
Endogenous
ghrelin receptor agonist |
Antagonists |
1922 |
[D-Lys3]-GHRP-6 |
Ghrelin
receptor antagonist |
Other |
3374 |
Cortistatin
14 |
Endogenous
neuropeptide; binds ghrelin receptor and sst1 - sst5 |
2951 |
[Des-octanoyl]-Ghrelin
(rat) |
Major
circulating form of ghrelin; devoid of activity at GHS receptor |
GIP Receptor Peptides |
Agonists |
2257 |
GIP
(1-39) |
Highly
potent insulinotropic peptide; GIP agonist |
2084 |
GIP
(human) |
Potent
insulinotropic gut hormone; GIP agonist |
6699 |
[D-Ala2]-GIP
(human) |
Highly
potent GIP agonist |
Antagonists |
5838 |
[Pro3]-GIP
(Mouse) |
GIP
receptor antagonist |
Glucagon Receptor Peptides |
Agonists |
6927 |
Glucagon
(Human, Porcine) |
Endogenous
glucagon receptor agonist |
Antagonists |
2216 |
des-His1-[Glu9]-Glucagon
(1-29) amide |
Glucagon
receptor antagonist |
Other |
2094 |
Oxyntomodulin
(porcine, bovine) |
Endogenous
gut peptide; modulates feeding and metabolism |
Glucagon-Like Peptide 1 Receptor Peptides |
Agonists |
1933 |
Exendin-4 |
Potent
GLP-1 receptor agonist |
5374 |
GLP-1
(7-37) |
Endogenous
bioactive GLP-1 receptor ligand |
1851 |
Glucagon-like
peptide 1 (1-37) (human, rat) |
Endogenous
pancreatic peptide |
2082 |
Glucagon-like
peptide 1 (7-36) amide (human, rat) |
Potent
insulinotropic peptide |
6517 |
Liraglutide |
Highly
potent, long-acting GLP-1 receptor agonist |
2094 |
Oxyntomodulin
(porcine, bovine) |
GLP-1
receptor agonist; endogenous preproglucagon derived peptide; modulates
feeding and metabolism |
Antagonists |
2081 |
Exendin-3
(9-39) amide |
Potent
GLP-1 receptor antagonist |
3266 |
GLP-1
(9-36) amide |
Metabolite
of GLP-1-(7-36) (Cat. No. 2082) |
Glucagon-Like Peptide 2 Receptor Peptides |
Antagonists |
7725 |
GLP-2
(3-33) |
Peptide
antagonist of glucagon-like peptide-2 (GLP-2) receptor |
Other |
2258 |
GLP-2
(human) |
Endogenous
hormone; displays intestinotrophic activity |
Gonadotropin- Releasing Hormone Receptor Peptides |
Antagonists |
3536 |
Cetrorelix
Acetate |
Potent
GnRH receptor antagonist |
GPR171 Peptides |
Agonists |
6304 |
BigLEN
(mouse) |
GPR171
agonist |
GPR83 Peptides |
Agonists |
6308 |
PEN
(mouse) |
GPR83
agonist |
Guanylyl Cyclase Peptides |
Activators |
1898 |
Guanylin
(human) |
Endogenous
activator of intestinal guanylyl cyclase |
Heterotrimeric G-protein GTPase Peptides |
Inhibitors |
3594 |
GRK2i |
GRK2
inhibitory polypeptide; Gβ/γ antagonist |
Other |
1193 |
Melittin |
Inhibits
Gs and stimulates Gi activity |
HIV Peptides |
|
2711 |
Bay
55-9837 |
Inhibits
HIV-1 viral replication; VPAC2 agonist |
2423 |
DAPTA |
Inhibits
HIV-1 viral cell entry |
Hypoxia Inducible Factor (HIF) Peptides |
Inhibitors |
5582 |
TAT-cyclo-CLLFVY |
Selective
HIF-1 dimerization inhibitor |
Other |
7287 |
FAM-DEALA-Hyp-YIPD |
Fluorescent
HIF-1α peptide |
7452 |
FAM-DEALAHypYIPMDDDFQLRSF |
Fluorescent
HIF-1α peptide |
Immune Checkpoint Peptides |
Inhibitors |
6515 |
(D)-PPA
1 |
PD-1/PD-L1
interaction inhibitor |
Inflammasomes Peptides |
Inhibitors |
2163 |
Z-VAD-FMK |
Irreversible
caspase inhibitor; cell-permeable |
Influenza Virus Peptides |
|
4611 |
PBP
10 |
Displays
antiviral activity against influenza viruses |
Inositol Lipid Peptides |
Activators |
1983 |
740
Y-P |
Cell-permeable
PI 3-kinase activator |
Insulin and Insulin-like Receptor Peptides |
Activators |
3435 |
Insulin
(human) recombinant, expressed in yeast |
Endogenous
peptide agonist |
Integrin Peptides |
Inhibitors |
6058 |
ATN
161 |
α5β1
integrin receptor antagonist |
3910 |
BIO
1211 |
Selective
α4β1 (VLA-4) inhibitor |
5870 |
Cilengitide |
Potent
and selective inhibitor of integrins αvβ3 and αvβ5 |
3202 |
Echistatin,
α1 isoform |
αVβ3 and
glycoprotein IIb/IIIa (integrin αIIbβ3) inhibitor |
4725 |
Eptifibatide |
Glycoprotein
IIb/IIIa inhibitor; inhibits platelet aggregation |
4664 |
Obtustatin |
Potent
and selective α1β1 inhibitor |
3498 |
RGDS
peptide |
Integrin
binding sequence; inhibits integrin receptor function |
Ligands |
7020 |
LDV |
α4β1 (VLA-4)
ligand |
Other |
4577 |
LDV
FITC |
Fluorescent
ligand for α4β1 (VLA-4) |
Inward Rectifier Potassium (Kir) Channel Peptides |
Blockers |
1316 |
Tertiapin-Q |
Selective
blocker of inward-rectifier K+ channels |
JNK/c-Jun Peptides |
Inhibitors |
1989 |
c-JUN
peptide |
Peptide
inhibitor of JNK/c-Jun interaction |
Kisspeptin Receptor Peptides |
Agonists |
7490 |
KISS1
305 |
Kisspeptin1
receptor agonist |
2570 |
Kisspeptin
10 (human) |
Endogenous
ligand for kisspeptin receptor |
4243 |
Kisspeptin
10 (rat) |
Endogenous
ligand for kisspeptin receptor |
1443 |
Metastin
(human) |
Potent,
endogenous ligand for kisspeptin receptor |
Antagonists |
3881 |
Kisspeptin
234 |
Kisspeptin
receptor antagonist; kisspeptin 10 (Cat. No. 2570) analog |
LDL Receptor Peptides |
|
3405 |
COG
133 |
ApoE
peptide fragmen |
Mas-Related G Protein-Coupled Receptors Peptides |
Agonists |
1763 |
BAM
(8-22) |
Potent
MRGPRX1 agonist |
3374 |
Cortistatin
14 |
Endogenous
neuropeptide; binds MRGPRX2, sst1 - sst5 and ghrelin receptor |
3137 |
Neuropeptide
FF |
MRGPRA
agonist; also antiopioid neuropeptide; endogenous NPFF1 and
NPFF2 agonist |
6551 |
PAMP-12
(human, porcine) |
Potent
MRGPRX2 agonist |
6552 |
PAMP-20
(human) |
MRGPRX2
agonist; also non-competitive nAChR antagonist |
5473 |
PMX
53 |
MRGPRX2
agonist; also potent C5a receptor antagonist |
Antagonists |
6642 |
QWF |
MRGPRX2
antagonist; also NK1 receptor antagonist |
Matrix Metalloprotease Peptides |
Inhibitors |
5523 |
TAPI
0 |
ADAM-17
(TACE) and MMP inhibitor |
6162 |
TAPI
1 |
ADAM-17
(TACE) and MMP inhibitor |
6013 |
TAPI
2 |
ADAM-17
(TACE) and MMP inhibitor |
Melanin-concentrating Hormone Receptor Peptides |
Agonists |
3806 |
MCH
(human, mouse, rat) |
Potent
endogenous MCH agonist |
Melanocortin (MC) Receptor Peptides |
Agonists |
3492 |
ACTH
(1-39) |
Potent
endogenous MC2 agonist |
2566 |
Melanotan
II |
High
affinity melanocortin receptor agonist |
3013 |
[Nle4,D-Phe7]-α-MSH |
Melanocortin
receptor agonist |
2584 |
α-MSH |
Endogenous
melanocortin receptor agonist |
Antagonists |
1831 |
HS
014 |
Selective
MC4 receptor antagonist |
1832 |
HS
024 |
Highly
potent MC4 receptor antagonist |
5954 |
MSG
606 |
Potent
human MC1 receptor antagonist; also MC3 and MC5 partial
agonist |
Other |
3420 |
SHU
9119 |
MC3 and
MC4 antagonist; MC5 partial agonist |
Microtubule Peptides |
|
6779 |
Davunetide |
Highly
potent active component of ADNP; increases tau-microtubule interactions |
Miscellaneous Compound Peptides |
|
5213 |
LL
37 |
Antimicrobial
peptide derivative of human cathelicidin |
3399 |
Myelin
Basic Protein (87-99) |
Major
antigenic component implicated in the pathophysiology of multiple sclerosis |
Miscellaneous Opioid Peptides |
Agonists |
1889 |
[Leu5]-Enkephalin |
Endogenous
opioid agonist peptide |
Other |
3137 |
Neuropeptide
FF |
Antiopioid
neuropeptide; also endogenous NPFF1 and NPFF2 agonist and MRGPRA
agonist |
Mitosis Peptides |
|
5130 |
CTCE
9908 |
CXCR4
antagonist; induces mitotic catastrophe in ovarian cancer cells |
1774 |
Dynamin
inhibitory peptide |
Dynamin
inhibitor |
1775 |
Dynamin
inhibitory peptide, myristoylated |
Cell-permeable
dynamin inhibitor |
Motilin Receptor Peptides |
Agonists |
2264 |
Motilin
(human, porcine) |
Endogenous
peptide regulator of gastrointestinal motility |
Myosin Light Chain Kinase Peptides |
Inhibitors |
1885 |
MLCK
inhibitor peptide 18 |
Selective
inhibitor of myosin light chain kinase |
Natriuretic Peptide Receptor Peptides |
Agonists |
1912 |
Atrial
natriuretic factor (1-28) (rat) |
Endogenous
peptide regulating blood pressure |
1906 |
Atrial
natriuretic factor (1-28) (human, porcine) |
Endogenous
peptide regulating blood pressure |
3522 |
Brain
natriuretic peptide (1-32) (human) |
Endogenous
peptide agonist at ANP receptor A (NPR1) |
3520 |
C-type
natriuretic peptide (1-22) (human, rat, swine) |
Endogenous
peptide agonist at NPR2 |
Antagonists |
6715 |
A
71915 |
Highly
potent and competitive NPRA antagonist |
5498 |
AP
811 |
High
affinity, selective NPR3 antagonist |
Neural Stem Cells Peptides |
|
4912 |
GsMTx4 |
Neuroprotective
compound; enhances neurogenesis in human neural stem cells |
1196 |
IRL-1620 |
Promotes
neural progenitor cell differentiation and maturation; ETB receptor
agonist |
Neuronal Metabolism Peptides |
|
2568 |
MOG
(35-55) |
Encephalitogenic
myelin oligodendrocyte glycoprotein fragment |
3399 |
Myelin
Basic Protein (87-99) |
Major
antigenic component implicated in the pathophysiology of multiple sclerosis |
1984 |
Nogo-66
(1-40) |
Competitive
antagonist for Nogo-66 receptor; promotes neuron regeneration |
2567 |
PLP
(139-151) |
Encephalitogenic
myelin proteolipid fragment |
Neuropeptide FF/AF Receptor Peptides |
Agonists |
3137 |
Neuropeptide
FF |
Endogenous
NPFF1 and NPFF2 agonist; also MRGPRA agonist |
4683 |
RFRP
3 (human) |
NPFF1 agonist;
GnIH homolog |
Neuropeptide S Receptors Peptides |
Agonists |
5857 |
Neuropeptide
S (Mouse) |
Endogenous
Neuropeptide S receptor agonist |
Neurotensin Receptor Peptides |
Agonists |
1998 |
JMV
449 |
Potent
neurotensin receptor agonist |
1909 |
Neurotensin |
Endogenous
neurotransmitter and endocrine modulator |
NF-κB and IκB Peptides |
Inhibitors |
6259 |
RAGE
antagonist peptide |
Receptor
for advanced glycation end products (RAGE) antagonist |
NFAT Peptides |
Inhibitors |
3930 |
NFAT
Inhibitor |
Inhibitor
of calcineurin-mediated NFAT activation |
5710 |
NFAT
inhibitor, Cell Permeable |
Cell
permeable NFAT inhibitor |
Nicotinic (α7) Receptor Peptides |
Antagonists |
2133 |
α-Bungarotoxin |
Selective
α7 nAChR antagonist |
|
3405 |
COG
133 |
α7
nAChR antagonist; ApoE peptide fragment |
Nicotinic Receptor (Non-selective) Peptides |
Antagonists |
6552 |
PAMP-20
(human) |
Noncompetitive
nAChR antagonist; also MRGPRX2 agonist |
Nicotinic Receptor (Other Subtype) Peptides |
Antagonists |
3120 |
α-Conotoxin
AuIB |
Selective
α3β4 nAChR antagonist |
1340 |
α-Conotoxin
MII |
Potent
and selective α3β2 and β3 nAChR antagonist |
3121 |
α-Conotoxin
PIA |
Selective
antagonist of α6-containing nAChRs |
NK1 Receptor Peptides |
Agonists |
1669 |
GR
73632 |
Potent
and selective NK1 agonist |
1178 |
[Sar9,Met(O2)11]-Substance
P |
Potent
and selective NK1 agonist |
Antagonists |
6642 |
QWF |
NK1 receptor
antagonist; MRGPRX2 antagonist |
NK2 Receptor Peptides |
Agonists |
1668 |
GR
64349 |
Potent,
selective NK2 agonist |
NK3 Receptor Peptides |
Agonists |
1068 |
Senktide |
Tachykinin
NK3 agonist |
NMDA Receptor Peptides |
Agonists |
3406 |
GLYX
13 |
NMDA
partial agonist; acts at the glycine site |
Non-selective AT Receptor Peptides |
Agonists |
1562 |
Angiotensin
(1-7) |
Vasorelaxant
peptide |
1563 |
Angiotensin
I (human, mouse, rat) |
Endogenous
precursor to angiotensin II (Cat. No. 1158) |
1158 |
Angiotensin
II |
Potent
vasoconstrictor peptide |
Non-selective CCK Peptides |
Agonists |
6264 |
Caerulein |
CCK
agonist |
1166 |
CCK
Octapeptide, sulfated |
C-terminal
octapeptide of CCK |
Non-selective CRF Receptor Peptides |
Agonists |
1151 |
CRF
(human, rat) |
Stimulates
ACTH release |
1604 |
Urocortin
(human) |
Endogenous
CRF agonist |
Antagonists |
1606 |
Astressin |
Potent
CRF antagonist |
Non-selective Endothelin Peptides |
Agonists |
1160 |
Endothelin
1 (human, porcine) |
Potent
vasoconstrictor peptide |
1164 |
Endothelin
2 (human) |
ETA/ETB agonist |
1162 |
Endothelin
3 (human, rat) |
Potent
vasoconstrictor |
Non-selective Orexin Peptides |
Agonists |
1455 |
Orexin
A (human, rat, mouse) |
Endogenous
agonist at OX1 and OX2 |
1456 |
Orexin
B (human) |
Endogenous
agonist at OX1 and OX2 |
1457 |
Orexin
B (mouse) |
Endogenous
agonist at OX1 and OX2 |
NOP Receptor Peptides |
Agonists |
0910 |
Nociceptin |
Endogenous
NOP agonist |
Antagonists |
1552 |
UFP-101 |
Potent,
selective silent antagonist for NOP |
NPY Receptor Peptides |
Agonists |
1153 |
Neuropeptide
Y (human, rat) |
Influences
feeding and sexual behavior |
1173 |
Neuropeptide
Y (porcine) |
Influences
feeding and sexual behavior |
1176 |
[Leu31,Pro34]-Neuropeptide
Y (human, rat) |
NPY
Y1 receptor agonist |
1154 |
Pancreatic
Polypeptide (human) |
NPY
Y4 agonist; involved in gastrointestinal tract function |
1618 |
Peptide
YY (3-36) |
Selective
NPY Y2 receptor agonist |
Nrf2 Peptides |
|
7627 |
FITC-labelled
Keap1-Nrf2 probe |
Fluorescent
Keap1-Nrf2 peptide |
Organoid Peptides |
|
2837 |
BDNF
(human) |
Improves
the functional maturation of neurons in the neuronal organoids |
|
3006 |
Gastrin
I (human) |
Used
in the culture of stomach and liver organoids; CCK2 receptor agonist |
Orphan 7-TM Receptor Peptides |
Agonists |
5151 |
Prosaptide
TX14(A) |
Potent
GPR37 and GPR37L1 agonist |
Other Angiotensin Receptor Peptides |
Antagonists |
5937 |
A
779 |
Selective
Mas receptor (Ang-(1-7) receptor) antagonist |
Other Apoptosis Peptides |
|
6515 |
(D)-PPA
1 |
PD-1/PD-L1
interaction inhibitor |
|
3051 |
TLQP
21 |
VGF-derived
peptide |
Other Channel Modulator Peptides |
|
2090 |
CALP1 |
Inhibits
Ca2+-sensitive ion channels; acts from cytoplasmic side |
|
4912 |
GsMTx4 |
TACAN
blocker; also TRPC1 and TRPC6 blocker |
Other Chemokine Receptor Peptides |
Agonists |
7116 |
Chemerin-9,
Human |
Potent
CMKLR1 agonist; c-terminal peptide of full length human chemerin |
7117 |
Chemerin-9,
Mouse |
Potent
CMKLR1 agonist; c-terminal peptide of full length mouse chemerin |
Other Notch Signaling Peptides |
Inhibitors |
6477 |
SAHM1 |
Notch
pathway inhibitor; prevents Notch complex assembly |
Other Nuclear Receptor Peptides |
Degraders |
7388 |
ND1-YL2 |
SRC-1
peptide-based Degrader; active in vivo |
Other Peptide Receptor Peptides |
|
3337 |
CART
(55-102) (rat) |
Neuromodulatory
neuropeptide fragment; satiety factor |
Other Protease Peptides |
Inhibitors |
2511 |
APC
366 |
Tryptase
inhibitor |
4139 |
Aprotinin |
Competitive
serine protease inhibitor |
3501 |
Decanoyl-RVKR-CMK |
Subtilisin/Kex2p-like
proprotein convertase inhibitor |
1167 |
Leupeptin
hemisulfate |
Inhibits
trypsin-like/cysteine proteases |
6423 |
Pep
2-8 |
Potent
PCSK9 inhibitor |
4645 |
Z-VRPR-FMK
trifluoroacetate salt |
Irreversible
MALT1 inhibitor |
Substrates |
3791 |
Hemopressin
(human, mouse) |
Bioactive
substrate for endopeptidase 24.15, neurolysin and ACE |
Other RTKs Peptides |
Modulators |
7712 |
Semax |
Hippocampal
BDNF/trkB system modulator |
Other Tachykinin Peptides |
Agonists |
1582 |
Neurokinin
B (human, porcine) |
Endogenous
tachykinin peptide |
1156 |
Substance
P |
Sensory
neuropeptide; inflammatory mediator |
Other Wnt Signaling Peptides |
|
5461 |
Foxy
5 |
Wnt5a
peptide mimetic |
OX1 Receptor Peptides |
Agonists |
5115 |
OXA
(17-33) |
Potent
and selective peptide OX1 agonist |
OX2 Receptor Peptides |
Agonists |
2142 |
[Ala11,D-Leu15]-Orexin
B |
Potent
and selective OX2 agoni |
Oxytocin Receptor Peptides |
Agonists |
4852 |
Carbetocin |
Oxytocin
analog |
1910 |
Oxytocin |
Involved
in uterine contraction and lactation |
Antagonists |
6332 |
Atosiban |
Potent
oxytocin receptor antagonist |
p53 Peptides |
|
7662 |
Azurin
p28 peptide |
Increases
p53 levels; binds p53 and inhibits COP1-mediated ubiquitination of p53 |
PACAP Receptor Peptides |
Agonists |
1183 |
PACAP
1-27 |
Potent
stimulator of adenylyl cyclase |
1186 |
PACAP
1-38 |
Potent
stimulator of adenylyl cyclase |
Antagonists |
3236 |
PACAP
6-38 |
Potent
PAC1 receptor antagonist |
Parathyroid Hormone Receptor Peptides |
Agonists |
6301 |
Parathyroid
hormone (1-34) (rat) |
Parathyroid
hormone (PTH) receptor agonist |
3011 |
Parathyroid
hormone (1-34) (human) |
Parathyroid
hormone (PTH) receptor agonist |
PI 3-kinase Peptides |
Activators |
1983 |
740
Y-P |
Cell-permeable
PI 3-kinase activator |
Piezo Channel Peptides |
Inhibitors |
4912 |
GsMTx4 |
Inhibits
Piezo1 channels; also TRPC1 and TRPC6 blocker |
7170 |
D-GsMTx4 |
Piezo2
and TRPC1/6 inhibitor; resistant to proteolytic digestion |
Protease-Activated Receptor Peptides |
Agonists |
7034 |
AY
254 |
Potent
PAR2 biased agonist; exhibits bias for ERK1/2 signaling |
7033 |
AY
77 |
Potent
PAR2 biased agonist; exhibits bias for Ca2+ signaling |
1487 |
AY-NH2 |
Selective
PAR4 agonist |
3015 |
2-Furoyl-LIGRLO-amide |
Potent
and selective PAR2 agonist |
3010 |
SLIGKV-NH2 |
PAR2 receptor
agonist |
1468 |
SLIGRL-NH2 |
PAR2-activating
peptide |
1464 |
TFLLR-NH2 |
PAR1-activating
peptide |
7742 |
TFRGAP-NH2 |
PAR3
peptide agonist |
1185 |
Thrombin
Receptor Agonist Peptide |
Causes
platelet aggregation and secretion |
3497 |
TRAP-6 |
PAR1 peptide
fragment (residues 42-47); acts as a PAR1 agonist |
Antagonists |
4751 |
FSLLRY-NH2 |
PAR2 peptide
antagonist |
1488 |
tcY-NH2 |
Selective
PAR4 antagonist |
Inhibitors |
2511 |
APC
366 |
Tryptase
inhibitor |
Controls |
3394 |
LRGILS-NH2 |
Control
peptide for SLIGRL-NH2 (Cat. No. 1468) |
3393 |
RLLFT-NH2 |
Control
peptide for TFLLR-NH2 (Cat. No. 1464) |
3392 |
VKGILS-NH2 |
Control
peptide for SLIGKV-NH2 (Cat. No. 3010) |
Protein Arginine Methyltransferase Peptides |
Inhibitors |
5128 |
C
21 |
Selective
PRMT1 inhibitor |
Protein Kinase A Peptides |
Inhibitors |
1904 |
PKA
inhibitor fragment (6-22) amide |
Potent
protein kinase A inhibitor |
6221 |
PKI
(5-24) |
High
affinity PKA inhibitor |
2546 |
PKI
14-22 amide, myristoylated |
Cell-permeable
protein kinase A inhibitor |
Other |
6286 |
st-Ht31 |
Inhibits
PKA/AKAP interactions; cell permeable |
Protein Kinase C Peptides |
Antagonists |
7962 |
TAT-SAMβA
Peptide |
Selective
antagonist of Mfn1-βIIPKC association |
Inhibitors |
1193 |
Melittin |
Inhibits
protein kinase C and cAMP-dependent protein kinase |
2549 |
ZIP |
Cell-permeable
inhibitor of atypical PKC isozyme PKMζ |
RAGE Peptides |
Antagonists |
6259 |
RAGE
antagonist peptide |
RAGE
antagonist |
Ras GTPase Peptides |
Inhibitors |
6920 |
SAH-SOS1A |
KRas/SOS1
interaction inhibitor |
Secretin Receptor Peptides |
Agonists |
1918 |
Secretin
(human) |
Gastrointestinal
peptide |
1919 |
Secretin
(rat) |
Gastrointestinal
peptide |
Somatostatin (sst) Receptor Peptides |
Agonists |
1818 |
Octreotide |
sst2,
sst3 and sst5 agonist |
1157 |
Somatostatin |
Influences
growth hormone release |
1165 |
Somatostatin
1-28 |
sst
agonist |
Antagonists |
3493 |
Cyclosomatostatin |
Non-selective
sst antagonist |
1843 |
CYN
154806 |
Selective
sst2 antagonist |
Other |
3374 |
Cortistatin
14 |
Endogenous
neuropeptide; binds sst1 - sst5, ghrelin receptor and MRGPRX2 |
Src Kinase Peptides |
Ligands |
1935 |
Caffeic
acid-pYEEIE |
Phosphopeptide
ligand for src SH2 domain |
Stapled Peptide Peptides |
|
6531 |
NLS-StAx-h |
Wnt
signaling inhibitor; inhibits β-catenin-transcription factor interactions |
6920 |
SAH-SOS1A |
KRas/SOS1
interaction inhibitor |
6477 |
SAHM1 |
Notch
pathway inhibitor; prevents Notch complex assembly |
STAT Peptides |
Activators |
3945 |
Colivelin |
STAT3
activator; also protects against β-amyloid neurotoxicity |
Stem Cell Proliferation Peptides |
|
7723 |
RGD
peptide |
Directs
association of stem cells with diverse biomaterials; increases cell spreading |
TGF-β Receptor Peptides |
Inhibitors |
7717 |
Disitertide |
TGF-β1
inhibitor |
Toll-like Receptor Peptides |
Agonists |
4637 |
Pam2CSK4 |
TLR2/6
agonist; induces TNF-α production |
4633 |
Pam3CSK4 |
TLR1/2
agonist; induces cytokine production |
Trk Receptor Peptides |
Agonists |
2837 |
BDNF
(human) |
Activates
TrkB and p75 receptors |
Antagonists |
5062 |
Cyclotraxin
B |
TrkB
receptor antagonist |
Other |
3051 |
TLQP
21 |
VGF-derived
peptide |
TRPC Channel Peptides |
Inhibitors |
4912 |
GsMTx4 |
TRPC1
and TRPC6 inhibitor; inhibits mechanosensitive ion channels |
7170 |
D-GsMTx4 |
TRPC1/6
and Piezo2 inhibitor; resistant to proteolytic digestion |
Two-P Potassium Channel Peptides |
Blockers |
5594 |
Spadin |
Potent
K2P2.1 (TREK-1) channel blocker |
Ubiquitin E3 Ligase Peptides |
|
7662 |
Azurin
p28 peptide |
Binds
p53 and inhibits COP1-mediated ubiquitination of p53 |
7287 |
FAM-DEALA-Hyp-YIPD |
Fluorescent
HIF-1α peptide; can be used to evaluate the effect of VHL binding on
degradation activity |
7452 |
FAM-DEALAHypYIPMDDDFQLRSF |
Fluorescent
HIF-1α peptide; can be used to evaluate the effect of VHL binding on
degradation activity |
7627 |
FITC-labelled
Keap1-Nrf2 probe |
Fluorescent
Keap1-Nrf2 peptide |
Urotensin-II Receptor Peptides |
Agonists |
1642 |
Urotensin
II (human) |
Endogenous
vasoactive agonist for the UT receptor |
Vasopressin Receptor Peptides |
Agonists |
3396 |
Desmopressin |
Synthetic
vasopressin analog; V1B and V2 agonist |
2935 |
[Arg8]-Vasopressin |
Antidiuretic
hormone |
Antagonists |
3377 |
(d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin |
Selective
vasopressin V1A antagonist |
VIP Receptor Peptides |
Agonists |
2711 |
Bay
55-9837 |
Potent
and selective VPAC2 agonist |
1911 |
VIP
(human, rat, mouse, rabbit, canine, porcine) |
Involved
in neurotransmission and smooth muscle relaxation |
Antagonists |
3054 |
[D-p-Cl-Phe6,Leu17]-VIP |
Selective
VIP receptor antagonist |
Voltage-gated Potassium (KV) Channel Peptides |
Blockers |
5676 |
Guangxitoxin
1E |
Potent
Kv2.1 and Kv2.2 channel blocker |
3563 |
Margatoxin |
Potent
KV1.3 channel blocker |
3220 |
ShK-Dap22 |
Extremely
potent and selective KV1.3 blocker; suppresses T cell activation in
vitro |
Voltage-gated Sodium (NaV) Channel Peptides |
Activators |
5941 |
OD1 |
Potent
hNav1.4, rNav1.6 and rNav1.7 channel activator |
Blockers |
4804 |
APETx2 |
NaV1.8
and NaV1.2 blocker; also blocks ASIC3 channels |
4913 |
Jingzhaotoxin
III |
Selective
NaV1.5 channel blocker |
4914 |
Phrixotoxin
3 |
Potent
blocker of NaV1.2, NaV1.3 and NaV1.5 channels |
4023 |
ProTx
II |
Selective
NaV1.7 channel blocker |